Eli Lilly Enters into $425M Small Molecule Arrangement with Schrödinger

A new drug design team-up has materialized for New York-based computational technology company Schrödinger. The company announced its $425 million deal to “align on a target of interest,” as put by Schrödinger’s President of Therapeutics R&D Karen Akinsanya, in a small molecule program with pharma giant...